secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2022-04-26T23:59:59+00:00
Accession:  0001104659-22-049935
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Pharma appoints Susan L. Drexler as Interim CFO effective Apr 21, 2022
----------------------------------------------------------------------------

- Susan L. Drexler appointed Interim CFO, principal accounting officer and principal financial officer effective April 21, 2022.
- Over 25 years of life science CFO experience; previously CFO of Harmony Biosciences (HRMY) and roles at Ocugen, Shire.
- Services provided via Danforth Advisors consulting agreement at $450/hour; termination requires 30 days (with cause) or 60 days (without cause) notice.
- No family relationship or reportable transactions between Drexler and any Kiora director or executive officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000110465922049935/0001104659-22-049935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000110465922049935/tm2213276d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-049935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer